Executive Bio
Dr. Roland Sackers serves as the Managing Director of QIAGEN Hannover GmbH. Dr. Sackers has been the Chief Financial Officer of QIAGEN N.V. since January 1, 2004 and has been Managing Director since 2006 and has been its Member of Management Board since 2006. Dr. Sackers served as a Vice President of Finance at QIAGEN N.V. from 1999 to 2004 and served as its Deputy Managing Director from January 1, 2004 to 2006. He has been Vice Chairman and Member of Supervisory Board at Exiqon A/S since February 7, 2017 and July 5, 2016 respectively. He has been a Non-Executive Director for Immunodiagnostic Systems Holdings plc since June 1, 2011 and also serves as Senior Independent Non-Executive Director. Dr. Sackers serves as a Director/Partner of Research Biolabs Pte. Ltd., QIAGEN Korea Ltd., QIAGEN Hong Kong Ltd. Pte., QIAGEN China (Shanghai) Co., Ltd., SA Biosciences, GenoVision Inc., QE Diagnostik Systeme GmbH, QIAGEN Shared Services, Inc., QIAGEN Benelux BV, QIAGEN Hamburg GmbH, QIAGEN Canada, Inc., Tian Gen Biotech (Beijing) Co. Ltd., 5 Prime, Inc., QIAGEN EURO Finance (Luxembourg) SA, QIAGEN Shenzen Co. Ltd., ATQ Biyoteknoloji Ic ve DIS TIC Ltd. STI., Digene UK (Holdings) Ltd., Digene (UK) Ltd., Digene Europe, Inc., QIAGEN Iberia, S.L., Qiagen Mexico, S. de R.L. de C.V., QIAGEN Australia Holdings Pty Ltd., Corbett Life Sciences Pty Ltd.,Corbett Research Pty Ltd.,Corbett Research Ltd. (UK).,Corbett Robotics, Inc. (US)., Corbett Robotics Pty Ltd., Corbett Diagnostics Pty Ltd.,QIAGEN Brasil Biotecnologia Ltda., QIAGEN Manchester Ltd. (formerly DxS), Dxs EBT Ltd., Dxs Ltd., Biotype GmbH, QIAGEN Lake Constance (formerly Ese) GmbH, QIAGEN US Finance Holding (Luxembourg) S.a.r.l., 5 Prime GmbH, QIAGEN Gaithersburg, In. Singapore, QIAGEN S.A., QIAGEN AS, QIAGEN Pty. Ltd., QIAGEN Inc., QIAGEN AG and QIAGEN Ltd. He served as Director/partner of QIAGEN Sciences K.K., IBS AG, Xeragon, Inc., Gentra Systems, Inc., Particle Solutions AS and GenoVision AS. He has been a Director of Qiagen Marseille Soci???t??? Anonyme since July 12, 2011. He serves as a Director of QIAGEN North American Holdings, Inc. From 2005 to 2007, he headed the expansion of QIAGEN's business in North America which today accounts for approximately 50 per cent of the group's overall sales. He served as a Member of the Supervisory Board at IBS Aktiengesellschaft (alternate name, IBS AG) from 2002 to May 18, 2006 and a Member of the Board of Directors of Operon Biotechnologies Inc. since 2004. Dr. Sackers graduated from the Westflische Wilhelms-Universitt Mnster, Germany with an MBA in 2006.